iLite® CD19 (+) Target Assay Ready Cells

BM5025

Engineered to express CD19, this iLite® target cell line supports ADCC and bispecific antibody assays targeting CD19-positive cells.

  • "Assay-ready" format for rapid and convenient use
  • Reproducible and biologically relevant results
  • Reduced assay variability and higher reproducibility compared to cells in culture
Add to quote
iLite® CD19 (+) Target Assay Ready Cells

Product Overview

The iLite® CD19 (+) Target Assay Ready Cells express the antigen CD19 on the cell surface and can be used as target cells in assay assessing antibodies towards CD19.

iLite CD19 (+) Target Assay Ready Cells are genetically engineered human cells (Raji, ATCC# CCL-86) optimized to over-express the surface antigen CD19.

The cells can be used as target cells together with iLite® CD3 Effector Assay Ready Cells for measurement of bi-specific CD3-CD19 antibody activity.

FOR RESEARCH USE ONLY

How it works

arrow
Principle of iLite® ADCC Bioassays

Principle of iLite® ADCC Bioassays

Our two-cell ADCC bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIIa (CD16) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.

Principle of iLite® ADCC Bioassays

Principle of iLite® ADCC Bioassays

A therapeutic antibody can bind to its antigen on the target cell surface. The fc-region of the antibody can bind to the FcγRIIIa receptor on the effector cells.

Principle of iLite® ADCC Bioassays

Principle of iLite® ADCC Bioassays

The antibody binding to the target and effector cells triggers a signal pathway in the effector cell, activating the Firefly luciferase gene. The strength of the resulting luciferase luminescence correlates with the antibody’s ability to activate ADCC.

arrow

How it works

arrow
Principle of iLite® T-cell activation bioassays

Principle of iLite® T-cell activation bioassays

Our two-cell T-cell activation bioassays consist of target cells expressing the antigen under study and effector cells expressing CD3/TCR Complex. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.

Principle of iLite® T-cell activation bioassays

Principle of iLite® T-cell activation bioassays

The T-cell activation process is triggered when the effector cell interacts with a bispecific drug antibody (BsAb) bound to its target cell. The CD3 complex on the surface of the effector cell binds to the CD3 part of the antibody, thus creating a bridge between the effector and target cells.Following the formation of this bridge, the engineered effector cells will, instead of activating the T-cell as in the in vivo situation, produce luciferase through an intracellular pathway and generate luminescence exclusively from this cross-linking and signaling. The strength of the luminescence correlates with the ability of the drug to activate the T-cells.

arrow

What's in the box?

>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium.

Specifications

Product code BM5025
Assay target CD19 ADCC
Technology Cell-based reporter gene assay
Detection system Luminescence
Regulatory status Research Use Only

Documents

Downloads

previous
Quantification of Bispecific Antibody Mediated T-cell Activation

Quantification of Bispecific Antibody Mediated T-cell Activation

Read post
A Cell-Based ADCC Bioassay Comparison

A Cell-Based ADCC Bioassay Comparison

Read post
Designing Optimal Bioassays for Measuring ADCC & ADCP Activity

Designing Optimal Bioassays for Measuring ADCC & ADCP Activity

Read post
Quantification of ADCP Activity of Therapeutic Antibodies Using Engineered Effector Cells and Target Cells

Quantification of ADCP Activity of Therapeutic Antibodies Using Engineered Effector Cells and Target...

Read post
Bispecific Antibodies – Quantifying Their Activity Using iLite® Bioassays

Bispecific Antibodies – Quantifying Their Activity Using iLite® Bioassays

Read post
Navigating the Complexities of Cell-based Assays in GMP QC Testing: The Journey to Robust Assays

Navigating the Complexities of Cell-based Assays in GMP QC Testing: The Journey to Robust Assays

Read post
The Value of Assay-Ready Cells in Providing Biologically Relevant Data for Robust Therapeutic Development

The Value of Assay-Ready Cells in Providing Biologically Relevant Data for Robust Therapeutic Develo...

Read post
How Biosimilars Are Expanding Options for Patient Care

How Biosimilars Are Expanding Options for Patient Care

Read post
Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeutics

Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeuti...

Read post
The Future of Drug Development for Complex Pathologies: Versatile Cell-based Assays and Customizable Cell Lines

The Future of Drug Development for Complex Pathologies: Versatile Cell-based Assays and Customizable...

Read post
Webinar - Advancements in GMP QC Testing: A Comprehensive Guide to Cell-Based Assays

Webinar - Advancements in GMP QC Testing: A Comprehensive Guide to Cell-Based Assays

Read post
next